Diagnostic and therapeutic approach to acute decompensated heart failure.

[1]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[2]  C. Lindsell,et al.  Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. , 2006, Annals of emergency medicine.

[3]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[4]  Gerasimos Filippatos,et al.  Pathophysiologic targets in the early phase of acute heart failure syndromes. , 2005, The American journal of cardiology.

[5]  K. Aaronson,et al.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.

[6]  K. Aaronson,et al.  Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.

[7]  Christopher M O'Connor,et al.  Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.

[8]  David A Morrow,et al.  BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. , 2004, Congestive heart failure.

[9]  W. Peacock,et al.  368 Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE® Registry , 2004 .

[10]  G. Fonarow,et al.  1069-114 Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure , 2004 .

[11]  Andrew K. Smith,et al.  Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure , 2004, European journal of heart failure.

[12]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[13]  T. McDonagh,et al.  N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. , 2003, European heart journal.

[14]  C. Frampton,et al.  Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. , 2003, Journal of the American College of Cardiology.

[15]  G. Fonarow,et al.  Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.

[16]  L. Stevenson,et al.  Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. , 2003, Journal of the American College of Cardiology.

[17]  E. Tuzcu,et al.  Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. , 2003, The New England journal of medicine.

[18]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[19]  W. Peacock,et al.  Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients , 2003 .

[20]  S. Hernández-Díaz,et al.  Nonsteroidal Antiinflammatory Drugs as a Trigger of Clinical Heart Failure , 2003, Epidemiology.

[21]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[22]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[23]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[24]  M. Pfeffer,et al.  Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. , 2002, Journal of the American College of Cardiology.

[25]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[26]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[27]  H. Naruse,et al.  Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. , 2002, The American journal of cardiology.

[28]  J. Ghali,et al.  Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. , 2002, Journal of the American College of Cardiology.

[29]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[30]  D. Ellison.  Diuretic Therapy and Resistance in Congestive Heart Failure , 2002, Cardiology.

[31]  M. Bristow,et al.  Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. , 2001, International journal of cardiology.

[32]  M. Drazner,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[33]  James B. Young,et al.  An update on nesiritide for treatment of decompensated heart failure , 2001, Expert opinion on investigational drugs.

[34]  P. Krishnaswamy,et al.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.

[35]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[36]  N. Albert,et al.  Observation unit management of heart failure. , 2001, Emergency medicine clinics of North America.

[37]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[38]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[39]  M. Domanski,et al.  Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. , 1999, Circulation.

[40]  L. Stevenson.  Tailored therapy to hemodynamic goals for advanced heart failure , 1999, European journal of heart failure.

[41]  A. Maggioni,et al.  Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. , 1999, American heart journal.

[42]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[43]  T. LeJemtel,et al.  Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. , 1999, Journal of the American College of Cardiology.

[44]  W. Abraham,et al.  Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.

[45]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[46]  G. Fonarow,et al.  Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. , 1997, Circulation.

[47]  F. Russel,et al.  Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. , 1996, Journal of the American College of Cardiology.

[48]  B. Massie,et al.  The heart failure epidemic: magnitude of the problem and potential mitigating approaches. , 1996, Current opinion in cardiology.

[49]  M. Bristow,et al.  Economic impact of heart failure in the United States: time for a different approach. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[50]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[51]  R. Myerburg,et al.  Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. , 1991, The American journal of medicine.

[52]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[53]  G. Ewy.  The abdominojugular test: technique and hemodynamic correlates. , 1988, Annals of internal medicine.

[54]  D. Faxon,et al.  Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. , 1987, The American journal of cardiology.

[55]  E. Braunwald,et al.  Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. , 1986, Circulation.

[56]  J. Cohn,et al.  Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. , 1985, Annals of internal medicine.

[57]  F. Tristani,et al.  Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. , 1982, The New England journal of medicine.

[58]  R. Hickey,et al.  Morphine decreases peripheral vascular resistance and increases capacitance in man. , 1979, Anesthesiology.

[59]  P. Cohn,et al.  Effect of Nitroprusside on Regional Myocardial blood Flow in Coronary Artery Disease: Results in 25 Patients and Comparison with Nitroglycerin , 1978, Circulation.